|Last Price$17.74||Day Change (%)0.17%|
|Open Price$17.74||Day Change ($)0.03|
|Day Range17.74–17.74||52-Week Range15.98–17.74|
As of Wed 05/24/2017 | USD
Broad Range of Clinical Data Evaluating Celgene Therapies to Be Presented at American Society of Clinical Oncology (ASCO)
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression
Results of the J-ALEX Study for Chugai's Alecensa® are Published in "The Lancet" Online
World Ovarian Cancer Drugs Market Analysis, Opportunities and Forecasts, 2014 - 2022 - Research and Markets
European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Squamous Cell Cancer of the Head and Neck in Adults Progressing On or After Platinum-based Therapy
Cold Chain Market in China 2017-2021: Market to Grow at CAGR of 17.13% - Growing Demand for Seafood - Research and Markets
A curious move, at a curious time, for purportedly, a curious reason, that is also a slap in the face to CPAs with the PFS credential.
This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...
To the extent that this content includes references to securities, those references do not constitute an offer or solicitation to buy, sell or hold such security. AdvisorShares is a sponsor of actively managed exchange-traded funds (ETFs) and holds positions in all of its ETFs. This document should ...
Get your practice on firm financial footing by getting a good budget in place.